Evidence map›Paper›PMID 39832060›Full record

ArticleInternational ophthalmology2025

Efficacy and safety of preservative-free anti-glaucomatous eye drops (dorzolamide/timolol) in ocular hypertension and/or glaucoma.

Sihem Lazreg, Ahmed Hassan Assaf, Ahmed M Abdelrahman, Mohamed Hosny, Mohamed Shafik Shaheen, Medhat Mohamed Shawky, Tamer Mohamed El-Raggal, Waleed Ali Moustafa Abou Samra, Yehia Salah Eldin Mostafa

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sihem LazregCornea and Ocular Surface Center Lazreg, 09000, Blida, Algeria. Sihemlazreg23@gmail.com.ORCID http://orcid.org/0000-0002-6310-9615
Ahmed Hassan AssafProfessor of Opthalmology, Ain Shams University, Consultant at Watany Eye Hospital, Cairo, Egypt.ORCID http://orcid.org/0000-0001-7663-5043
Ahmed M AbdelrahmanProfessor of Ophthalmology, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0003-3459-2924
Mohamed HosnyProfessor of Ophthalmology, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-7243-0224
Mohamed Shafik ShaheenProfessor of Ophthalmology, Alexandria University, Alexandria, Egypt.
Medhat Mohamed ShawkyProfessor of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Tamer Mohamed El-RaggalProfessor of Ophthalmology, Ain Shams University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-0084-9683
Waleed Ali Moustafa Abou SamraProfessor of Ophthalmology, Mansoura University, Director of Mansoura Ophthalmic Center, Mansoura, Egypt.ORCID http://orcid.org/0000-0001-7730-6049
Yehia Salah Eldin MostafaChairman and Professor of Ophthalmology, Kasr Alainy Faculty of Medicine, Cairo University, Giza, Egypt.ORCID http://orcid.org/0000-0001-6482-1543

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study evaluated the efficacy, safety, and tolerability of a single-dose, preservative-free (PF) Dorzolamide/Timolol combination (Twinzol-SDU).

methodsA 3-month single-arm, multicenter, prospective cohort study was conducted in Egypt between January 2021 and October 2022 on previously diagnosed and controlled patients with ocular hypertension and/or glaucoma. Efficacy was assessed using the change in intraocular pressure (IOP) after 6 and 12 weeks. Safety was identified through the change in the incidence of ocular side effects, ocular surface disease index (OSDI) scores and grades, and Time Break-Up time (TBUT).

resultsA total of 382 patients were enrolled in the analysis. After the three-month period of therapy, a significant reduction in IOP was seen (mean change: -1.9, P < 0.001) after switching to PF Dorzolamide/Timolol combination. The rate of ocular abrasion decreased significantly from 30.6% to 1.3% (P < 0.001). The rate of normal aqueous tear production increased from 24.1% to reach 79.4% (P < 0.001). The OSDI scores decreased significantly throughout the study period, with a median score decreased from 41.7 (21.7) to 12.5 (12.5) (P < 0.001). Mild OSDI grades significantly increased from the baseline of 12.6% to reach 24.7%. Moderate OSDI grade decreased at the same rate, from 12.8% to 11.1%. The number of patients with severe OSDI grade substantially decreased from 64.4% to 4.5%, with a P < 0.001. TBUT increased from 9 (3.7) seconds to reach and 12.3 (4) seconds after 12 weeks of treatment (P < 0.001).

conclusionGenerally, the PF dorzolamide/timolol combination was associated with a significant reduction in IOP and tolerability among glaucoma patients.

Indexed as

GlaucomaIntraocular PressureOcular HypertensionSulfonamidesThiophenesTimololAdultAgedAntihypertensive AgentsDrug CombinationsFemaleFollow-Up StudiesHumansMaleMiddle AgedOphthalmic SolutionsAntihypertensive Agentsdorzolamidedorzolamide-timolol combinationDrug CombinationsOphthalmic SolutionsSulfonamidesThiophenesTimololDorzolamideGlaucomaOcular HypertensionTimolol

Identifiers

PMID39832060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.